Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
The development of COVID-19 treatment
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest …
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of …
Objectives To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …
drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations …
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
Objective To develop evidence-based European Alliance of Associations for Rheumatology
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …
[HTML][HTML] Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers
P Koźmiński, PK Halik, R Chesori… - International journal of …, 2020 - mdpi.com
Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively
used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune …
used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune …
Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active …
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of …
Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
JS Smolen, RBM Landewé, JWJ Bijlsma… - Annals of the …, 2020 - ard.bmj.com
Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …
rheumatoid arthritis (RA) management recommendations to account for the most recent …
[HTML][HTML] COVID-19 and the Swedish enigma
M Claeson, S Hanson - The Lancet, 2021 - thelancet.com
In the second wave of the COVID-19 pandemic, the Swedish national response continues to
be an outlier with cases and deaths increasing more rapidly than in its Nordic neighbours. 1 …
be an outlier with cases and deaths increasing more rapidly than in its Nordic neighbours. 1 …
Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of …
This systematic literature review (SLR) regarding the efficacy, duration of use and safety of
glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR …
glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR …
[HTML][HTML] Interleukin-6 in rheumatoid arthritis
The role of interleukin (IL)-6 in health and disease has been under a lot of scrutiny in recent
years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in …
years, particularly during the recent COVID-19 pandemic. The inflammatory pathways in …